The present randomized, controlled, parallel-grouped trial includes 81 patients (aged 18 to 75 years) suffering from oral potential premalignant lesions. Patients will be randomly assigned into 3 equal groups: Group A:Thymoquinone group 100mg Group B:Thymoquinone group 200mg Group C:Control group (placebo)